malignant tumor(including breast cancer and esophagus cancer, etc)
Conditions
Interventions
Malignancy group:none
Control group:none
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Case group: 1. Primary tumor of each organ, multiple malignant tumors of a single organ are considered as a single primary tumor; 2. The tumor must be pathologically sliced or cytologically confirmed to be malignant and not metastasis of other organs; 3. Complete imaging assessment and pathological staging classification; 4. Informed consent from the patient must be obtained prior to starting any study-related procedures and treatments, confirming that the patient is willing to participate in the study and to comply with the research-related requirements. Control group: 1. Complete physical examination assessment to confirms tumor non-existence; 2. Patients with benign tumors need to have complete imaging assessment and histological pathology confirmation; 3. Obtain informed consent from the patient prior to starting any study-related procedures and treatments, confirming that the patient is willing to participate in the study and is subject to research-related requirements.
Exclusion criteria
Exclusion criteria: 1. History of other malignant tumors; 2. Incomplete medical history or imaging data; 3. The patient withdraws from the study due to other physical or social reasons unrelated to the project; 4. Mental illness or other condition that affects patient compliance; 5. Other serious diseases or medical conditions; 6. History of uncontrollable paroxysmal disease, including CNS diseases or mental disorders, and other situations in which investigator determines that the understanding and signing of informed consent might be affected; 7. Those who have undergone blood transfusion or stem cell therapy in the past one year; 8. Any other conditions that the investigator considers inappropriate for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ctDNA methylation; | — |
Countries
China
Contacts
Public ContactLiu Jiaqi
Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed